Invion ( (AU:IVX) ) has provided an announcement.
Invion Limited has issued 87,273 fully paid ordinary shares at no cost per share, as part of its compliance with the Corporations Act. The company is in preliminary discussions with RMW Cho Group Limited to potentially expand its rights to the Photosoft™ technology to new territories or indications. These discussions are still in early stages, and there is no guarantee of a binding agreement. This move could impact Invion’s operational scope and market positioning if successful.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft™ technology for cancer treatment. The company holds the license rights for this technology in Australia and New Zealand, with research and clinical trials funded by RMW Cho Group Limited. Invion is listed on the ASX under the code IVX.
YTD Price Performance: -28.00%
Average Trading Volume: 1,000
Technical Sentiment Signal: Buy
Current Market Cap: $5.11M
For detailed information about IVX stock, go to TipRanks’ Stock Analysis page.